VALUE DRIVING MILESTONES IN 2020Our deck is stacked!
Q2 Submit FDA IND for Phase 3 clinical study of Bucillamine in the treatment of COVID-19
Q3 Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19 in the U.S.
Q3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
Q3 Patient enrollment of Phase 3 study of Bucillamine in the treatment of COVID-19
Q4 Initial results from Phase 3 clinical study of Bucillamine in the treatment of COVID-19
Q4 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
https://www.revivethera.com/uploads/1/0/1/0/101019330/rvv_deck_-_august20201.pdf